Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year, » Read more about: Massive Upside In Big Money Pharma Favorite? »
Read More
Alert: 77.7% Upside In Under-the-Radar Growth Stock
Investment Alert: Buy dLocal Under $13
Disclaimer: Investment Alerts have a medium to long-term time horizon. These do not constitute financial advice and you should contact a financial advisor before deciding whether it is appropriate for your individual circumstances.
Growth stocks aren’t in vogue right now but some exhibit growth rates so high that they can’t help but seize your attention.
» Read more about: Alert: 77.7% Upside In Under-the-Radar Growth Stock »
Read More
Market Commentary: 19 Stocks with Ridiculous Cash Flows
When the economic winds of fortune change, the old saying goes that cash is king but maybe it should be cash flows are king. A company that can spit out enormous sums of cash with predicability may offer a safe haven at a perilous time. To find out what companies stand out, a little-known metric called CROCI is very useful.
» Read more about: Market Commentary: 19 Stocks with Ridiculous Cash Flows »
Read MoreAlert: Billionaire Bets BIG On Under-the-Radar Stock
Investment Alert: Buy Global Payments [GPN] Under $100/share
Disclaimer: Investment Alerts have a medium to long-term time horizon. These do not constitute financial advice and you should contact a financial advisor before deciding whether it is appropriate for your individual circumstances.
Larry Robbins isn’t a name that most investors know well,
» Read more about: Alert: Billionaire Bets BIG On Under-the-Radar Stock »
Read More
1 Cloud SaaS Healthcare Stock to Buy on the Dip?
It might surprise many that Veeva Systems Inc. (NYSE:VEEV), best known for its cloud-based software solutions tailored to the life sciences industry, has maintained a core principle of putting customer success and product excellence ahead of short-term gains.
In a market crowded with SaaS companies seeking to serve a wide variety of enterprises,
» Read more about: 1 Cloud SaaS Healthcare Stock to Buy on the Dip? »
Read MoreThe Ivy
Can a Bitcoin ETF 30x Your Money?
If you’re bullish on Bitcoin but want more than just price appreciation, the MSTY ETF might be the most interesting option on the table.
MSTY (YieldMax MSTR Option Income Strategy ETF) is a covered call fund on MicroStrategy, a company whose stock is effectively a leveraged bet on Bitcoin.
Since launching in 2024,
» Read more about: Can a Bitcoin ETF 30x Your Money? »
Read MoreThe Spotlight
Spotlight: Market Crash Incoming?
Some stock market indicators are better than others but have you heard of one being perfect for over a century? If the cyclically adjusted price-to-earnings ratio, better known as CAPE, is to be believed, then the markets could be set for a rocky road this year.
Unlike traditional PE ratios, the CAPE figure factors in inflation and smooths the peaks and troughs of unforeseen or surprising events –
» Read more about: Spotlight: Market Crash Incoming? »
Read MoreThe Daily
Europe Loses Big In US-China Economic War
Sino-American diplomacy increasingly marginalizes outside actors, especially Europe.
AFP via Getty Images
In June 2025, as Beijing and Washington sat down for their first round of trade talks in London, which ultimately produced only a truce, Europe sought a diplomatic breakthrough with China.
» Read more about: Europe Loses Big In US-China Economic War »